Provectus Biopharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Provectus Biopharmaceuticals, Inc.
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.
The group will take a $770m impairment charge thanks to the Phase III failure of AVP-786 – but further trials continue.
Japanese generics firm Towa has acquired Kamata as a wholly owned subsidiary, in order to increase soft capsule manufacturing capacity for its Sunsho segment. The firm has also announced that it has completed expansion works at its Yamagata plant and made a moderate revision to its financial forecast.
Safety signals were the most common cause of discontinued candidates in the breakthrough therapy designation program in 2023.
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Provectus Biopharmaceuticals Australia Pty Ltd.
- Provectus Pharmaceuticals, Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.